Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00353808
Status:
TERMINATED
Last Update Posted:
2011-04-07
First Post:
2006-07-17
Brief Title:
A Trial Assessing The Long Term Safety And Tolerability Of SS-Reboxetine In Patients With Post-Shingles Pain
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
An Open-Label Extension Trial Assessing The Safety And Tolerability Of SS-Reboxetine In Patients With Postherpetic Neuralgia PHN
Status:
TERMINATED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study has been terminated early as the esreboxetine development program is being discontinued There are no safety or efficacy concerns
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the long-term safety and tolerability of SS-Reboxetine in patients with chronic pain following shingles This is the extension study of Protocol A6061026
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None